Clinical presentation and management of atypical hemolytic uremic syndrome in Latin America: a narrative review of the literature

Simple item page
dc.catalogadoryvc
dc.contributor.authorSepúlveda Palamara, Rodrigo Andrés
dc.contributor.authorModelli de Andrade, Lg.
dc.contributor.authorFortunato, Rm.
dc.contributor.authorGómez, B.
dc.contributor.authorNieto-Ríos, Jf.
dc.date.accessioned2024-06-12T22:30:51Z
dc.date.available2024-06-12T22:30:51Z
dc.date.issued2024
dc.description.abstractIntroduction: comprehensive information about atypical hemolytic uremic syndrome (aHUS) is rela-tively scarce outside of Europe and North America. This narrative review assembles available published data about the clinical presentation and management of aHUS in Latin America. Areas covered: A search conducted in February 2023 of the MEDLINE (from inception), Embase (frominception), and LILACS/IBECS (1950 to 2023) databases using search terms 'atypical hemolytic uremicsyndrome’ and ‘Latin America’ and their variations retrieved 51 records (full papers and conferenceabstracts) published in English, Spanish, or Portuguese. After de-duplication, manual screening of titles/abstracts and addition of author-known articles, 25 articles were included of which 17 (68%) are full papers. All articles were published during the years 2013–2022. Articles include cohort studies, a registry analysis,and case reports from Argentina, Brazil, Chile and Columbia. Overall, Latin American patients with aHUSpresent the classic epidemiological, clinical, and genetic characteristics associated with this condition asdescribed in other world regions. Depending on the country and time of reporting, aHUS in Latin Americawas treated mainly with plasma therapy and/or eculizumab. Where reported, eculizumab substantiallyimproved aHUS-related outcomes in almost all adult and pediatric patients.Expert opinion: Eculizumab has dramatically altered the natural course of aHUS, improving prognosisand patient outcomes. Addressing economic challenges and investing in healthcare infrastructure willbe essential to implement strategies for timely detection and early treatment of aHUS in Latin America.
dc.fechaingreso.objetodigital2024-06-12
dc.fuente.origenORCID
dc.identifier.doi10.1080/17474086.2024.2365169
dc.identifier.urihttps://doi.org/10.1080/17474086.2024.2365169
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/86749
dc.identifier.wosidWOS:001247675000001
dc.information.autorucEscuela de Medicina;Sepúlveda Palamara,Rodrigo Andrés;0000-0002-9618-3686;252768
dc.language.isound
dc.nota.accesocontenido completo
dc.revistaExpert Review of Hematology
dc.rightsacceso abierto
dc.rights.licenseCC BY NC ND Attribution-NonCommercial-NoDerivs 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAtypical hemolytic uremicsyndrome
dc.subjecteculizumab
dc.subjectLatin America
dc.subjectravulizumab
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleClinical presentation and management of atypical hemolytic uremic syndrome in Latin America: a narrative review of the literature
dc.typeartículo
sipa.codpersvinculados252768
sipa.trazabilidadORCID;2024-06-10
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
TEXTO COMPLETO_Clinical presentation and management.pdf
Size:
1.83 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas